Simponi (golimumab) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST N	AME:
	, chart notes or lab data, to su		ny additional documentation that is n request). Information contained in
MEMBER INFORMATION			
LAST NAME:		FIRST NAME:	
PHONE NUMBER:		DATE OF BIRTH:	
STREET ADDRESS:		<u> </u>	
CITY:		STATE: ZI	P CODE:
PATIENT INSURANCE ID NUM	ИBER:	<u> </u>	
<u> </u>	/NOPP	OSURE AUTHORIZATION FORM W	TH THIS REQUEST WHICH CAN BE FOUND AT THE
AUTHORIZED REPRESENTATIV	/E'S PHONE NUMBER:		
PRESCRIBER INFORMATION			
LAST NAME:		FIRST NAME:	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	
STREET ADDRESS:		l	
CITY:		STATE: ZI	P CODE:
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:	
	_	l	
MEDICATION OR MEDICAL I	DISPENSING INFORMATION		
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
☐ NEW THERAPY	RENEWAL	IF RENEWAL: DATE	THERAPY INITIATED:
DURATION OF THERAPY (SPE	CIFIC DATES):		

Continued on next page.



Simponi (golimumab) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
	d arthritis ICD-10 Code(s):	
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	I: PLEASE PROVIDE ALL RELEVANT CLINICA	AL INFORMATION TO SUPPORT A
	ncurrently with another biologic or imm Cimzia, Enbrel, Humira, Actemra or Xelja	· -
•	equate response to at least a three mon □ Yes □ No *Must submit dates of	
For active ankylosing spondylitis, also Has the patient tried and failed at lea Yes No *Must submit docume Has the patient tried and failed method	st two (2) NSAIDS or does the patient haentation.	ave a contraindication to NSAIDs?* documentation.
Has the patient had a trial and inaded	atic arthritis, also answer the following: quate response to oral disease-modifying cyclosporine or leflunamide(Arava)?*	-
*Must submit documentation.		
Must submit documentation. Is the patient unable to take a non-bi	ologic DMARD due to chronic liver disea SH, or elevated liver enzymes? Yes	



Simponi (golimumab) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: M	IEMBER'S FIRST NAME:
Has the patient had a trial and inadequate response to methor modifying anti-rheumatic agent (DMARD) such as Imuran, Ric *Must submit documentation.	
Is the patient unable to take a non-biologic DMARD due to che liver, nonalcoholic steatohepatitis/NASH, or elevated liver en *Must submit documentation.	zymes?* 🗆 Yes 🗆 No
If "no" to the above question, please provide rationale (if take a DMARD:	
Reauthorization: If this is a reauthorization request, answer the following ques	itions:
Will the patient be taking Simponi concurrently with another Kineret, Remicade, Rituxan, Orencia, Cimzia, Enbrel, Humira,	biologic or immunomodulatory agent, such as
Has the patient had a positive clinical response, and is remiss ☐ Yes ☐ No *Please provide documentation.	ion of disease maintained with continued use?*
Select if Simponi is prescribed by the following specialists: □ Dermatologist □ Rheumatologist	
Are there any other comments, diagnoses, symptoms, medica physician feels is important to this review?	ations tried or failed, and/or any other information the
Please note: Not all drugs/diagnosis are covered on all plans. T information is received.	his request may be denied unless all required
ATTESTATION: I attest the information provided is true and acthe Health Plan, insurer, Medical Group or its designees may perfect the information provided in true and action in the information provided is true and action in the information provided in true and action in the information provided is true and action in the information provided in true and action in the information provided is true and action in the information provided in the information in the informat	•
information necessary to verify the accuracy of the information	·
Prescriber Signature or Electronic I.D. Verification:	Date:
CONFIDENTIALITY NOTICE: The documents accompanying this transmission you are not the intended recipient, you are hereby notified that any disclosu of these documents is strictly prohibited. If you have received this informatic and arrange for the return or destruction of these documents.	re, copying, distribution, or action taken in reliance on the contents

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

